Shots:

• Regeneron reports that its investigational Ab cocktail for COVID-19 may be available for use by the end of summer as it ramps up the efforts to initiate the clinical studies in June’2020- revealed in its Q1 results
• The company will evaluate the Ab cocktail in three different settings to assess its effectiveness in the early stages of the disease- hospitalized patients with severe disease as well as in preventing infection
• The company is developing an Ab cocktail with the focus to make clinical data available within a month or two following the initiation of studies and will scale up its manufacturing to produce 200-000 doses/mos. Additionally- Regeneron is evaluating Kevzara in patients with RA and unveiled ~15% decline in Eylea’s demand in Apr amid COVID-19

Click here ­to­ read full press release/ article | Ref: Regenron  | Image: Stat

Related News: Regeneron to Initiate COVID-19 Antibody Program in Early Summer